|
Büttner, Reinhard, M.D., *15. Jan. 1960
Institute of Pathology
Professor and Chairman
University Hospital Bonn, University of Bonn
Sigmund Freud Strasse. 25
D-53125 Bonn (Germany)
Phone: (49) 228-287-15375
Telefax: (49) 228-287-15030
E-mail:
Diese E-Mail-Adresse ist gegen Spam Bots geschützt, Sie müssen JavaScript aktivieren, damit Sie es sehen können
Education and Degrees
1979 – 1985 Laureate of the German National Scholarship Foundation
1979 – 1981 Preclinical Studies in Medicine, Anthropology and African Ethnology, Johannes-Gutenberg-Universität, Mainz (Germany)
1981 – 1983 Clinical Studies, Ludwig-Maximilians-Universität, München (Germany)
1982 – 1983 Doctoral Thesis at the Pettenkofer Institute (München)
“Determination of Rotavirus Strains by Gel Electrophoresis”
1983 – 1984 Clinical Studies, Middlesex-Hospital-Medical School, London (UK)
1984 – 1985 Practical Year, Final Medical Examinations, University of Cologne (Germany)
01/1986 American Medical Examinations (ECFMG), Bonn (Germany)
03/1995 Habilitation in Experimental Pathology
07/1996 State board examination in General and Organ Pathology
Professional Positions
01/1986 - 04/1987 Residency in Pathology, RWTH Aachen (Germany)
05/1987 - 12/1988 Postdoctoral Fellow at the Genzentrum (München), Prof. Winnacker
01/1989 - 12/1990 Postdoctoral Fellowship Deutsche Forschungsgemeinschaft,
M.D. Anderson Cancer Center, Houston (TX), Prof. Garth Nicolson
01/1991 - 12/1998 Residency and Lecturer in Pathology, Univ. Regensburg (Germany)
01/1999 - 07/2001 C3-Professor, Institute of Pathology, RWTH Aachen
08/2001 - present C4-Professor and Director, Institute of Pathology, Univ. Bonn
Honours and Awards
1997 - 99 Speaker of the DFG Research Group “Neuronal Apoptosis”
2005 Founder and Scientific Advisor of Targos Molecular Diagnostics, Inc.
2005 Member of the German Academy of Sciences “Leopoldina”
10/2005 – 09/2008 Dean of the Medical Faculty, University of Bonn
2007 Co-Applicant and Board Member of the National
Center for Integrated Oncology, CIO Köln/Bonn
2007 Speaker of the German research Consortium “Sarcomas”
2008 Member of the Scientific Advisory Board for the
National Center for Tumor Diseases Heidelberg (NCT)
Main Research Areas and Recent Publications
• Epigenetic and Transcriptional Mechanisms of Gene Regulation and Tumor Differentiation
We were the first to show that histone demethylases epigenetically regulate gene expression patterns in tumors. They can be used as predictive markers in oncology and as novel therapeutic targets for tumour therapy.
Selected reading:
[1] Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schuele R (2005) LSD1 demethylates repressive histone marks to promote androgen receptor-dependent transcription. Nature 437: 436-439.
[2] Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schuele R, Buettner R. (2006) Androgen receptor coactivators LSD1 and FHL2 predict risk of prostate cancer recurrence. Cancer Res 66: 11341-11347
[3] Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, Günther T, Buettner R, Metzger E, Schüle R (2007). Co-operative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9: 347-353
[4] Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, Friedrichs N, Patnaik D, Higgins JM, Potier N, Scheidtmann KH, Buettner R, Schüle R. (2008) Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 10: 53-60 (2008).
[5] Schulte JH, Lim SY, Schramm A, Friedrichs N, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel R. The LSD1 histone demethylase is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res (accepted).
• Pathology of Familial Cancers and Sarcomas
The Institute of Pathology serves as the National Reference Center for familial colorectal, breast and ovarian cancer and contributed diagnostic standards as part of the German HNPCC and HBOCC study groups. The director is the speaker of the German Sarcoma Study Group (GSSG) and initiated a comprehensive programme to implement novel tumor-selective targeted therapies.
Selected Reading:
[1] Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Schulte JH, Heukamp LC, Lasson O, Tanaka S, Kawai A, Wardelmann E, Büttner R, Pietsch T, Hartmann W. Insulin-like growth factor-I receptor-I acts as a growth regulator in synovial sarcoma. J Path (in press).
[2] Müller A., Zielinski D, Friedrichs N, Oberschmid B, Merkelbach-Bruse S, Dietmaier W, Zöltzer H, Schulmann K, Schackert KH, Linnebacher M, von Knebel-Döberitz M, Buettner R, Rüschoff J and the German HNPCC Consortium. Reduced mRNA expression in paraffin-embedded tissues identifies MLH1 and MSH2-deficient colorectal tumors and potential mutation carriers. Virchows Arch (epub June26, 2008).
[3] Engel C, Rahner N, Schulmann K, Steinke V, Möslein G, Rüschoff J, Büttner R, Löffler M, Schmiegel W, Propping P, and the German HNPCC Consortium. Stage-associated risk reduction of HNPCC by annual colonoscopic surveillance: Results from a prospective cohort study of the German HNPCC consortium. NEJM (under review).
[4] Braun M, Flucke U, Debald M, Walgenbach-Bruenagel G, Walgenbach KJ, Höller T, Pölcher M, Wolfgarten M, Sauerwald A, Keyver-Paik M, Kühr M, Büttner R, Kuhn W. Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin) – a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res Treat (epub Dec29, 2007).
[5] Schildhaus HU, Buettner R, Wardelmann E, Merkelbach-Bruse S. Inflammatory fibroid polyps harbor mutations in PDGFRA. J Pathol (in press 2008).
[6] Rahner N, Friedrichs N, Steinke V, Aretz S, Friedl W, Buettner R, Mangold E, Propping P, Walldorf C. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 214: 10-16 (2008).
• Predictive Pathology, Molecular Diagnostics, Molecular Cell Biology
The Institute of Pathology has made many important publications in the area of predictive pathology and molecular diagnostics. The director is the co-founder and advisor of Targos GmbH, Europe´s leading provider for biomarker detection and services. Targos has initiated a research consortium for the development of biomarkers and novel targeted drugs (see attached research program).
Selected reading:
[1] Moser M, Matthiesen S, Kirfel J, Schorle H, Bergmann C, Senderek J, Rudnik-Schöneborn S, Zerres K, Buettner R (2005). A mouse model for congenital liver fibrosis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology 41: 1113-1121
[2] Wixler V, Hirner S, Müller JM, Gullotti L, Will C, Kirfel J, Günther T, Schneider H,, Bosserhoff AK, Schorle H, Park J, Schüle R and Buettner R (2007) Deficency in the LIM-only protein FHL2 impairs skin wound healing. J Cell Biol 177: 163-172
[3] Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Zimmer A, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, di Marzo V, Tüting T Zimmer A (2007) Attenuation of allergic contact dermatitis through the Endocannabinoid System. Science 316: 1494-1497
[4] Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, Müller SC, von Ruecker A. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and pronostic indicators. Int J Cancer 122: 138-43 (2008).
[5] Hofmann M, Stoss O, Shi D, Büttner R, van de Vjiver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a Her2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805 (2008).
[6] Ney JT, Kurts C, Zhou Q, Schmidt T, Eckert D, Felsher D, Schorle H, Knolle P, Tüting T, Büttner R, Limmer A, Gütgemann I. Autochthonous liver tumors induce T-cell tolerance associated with T-cell receptor downmodulation. Hepatology (in press 2008).
|
